# US 2025/0146085 A1 · Methods for early detection of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0146085 A1
- Document ID: US20250146085A1
- Status: Published application
- Kind: A1
- Application number: 19/018,456
- Filed: 2025-01-13
- Published: 2025-05-08
- Earliest claimed: 2016-04-14
- Assignees: Guardant Health, Inc.
- Applicants: Guardant Health, Inc.
- Inventors: Stefanie Ann Ward MORTIMER; AmirAli TALASAZ; Darya CHUDOVA; Helmy ELTOUKHY
- Web page: https://patentgrep.com/patent/US20250146085A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12M 1/00: Apparatus for enzymology or microbiology
- C12M 1/34: Measuring or testing with condition measuring or sensing means, e.g. colony counters
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/6855: Ligating adaptors
- C12Q 1/6869: Methods for sequencing
- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- G16B 20/20: Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
- G16B 30/10: Sequence alignment; Homology search
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G16H 50/30: for calculating health indices; for individual health risk assessment
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/154: Methylation markers
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- C12Q 2600/166: Oligonucleotides used as internal standards, controls or normalisation probes
- Y02A 90/10: Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12M: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed herein are methods, compositions, and devices for use in the early detection of cancer. The methods include preparing cell-free nucleic acid molecules from a subject for sequencing, sequencing a panel of regions in the cell-free nucleic acid molecules, and detecting one or more markers that are indicative of a cancer.

## Claims

### Claim 1

A method for detecting residual cancer after surgery by interrogating methylation status and genetic variants in cell-free deoxyribonucleic acid (cfDNA) molecules of a sample from a subject, the method comprising:
(a) enriching the cfDNA molecules or amplicons thereof using oligonucleotide sequence capture probes for a plurality of genes or genomic regions, wherein the plurality of genes or genomic regions:
(i) comprise CpG islands which are differentially methylated regions, and
(ii) are known to be associated with one or more cancers;
(b) sequencing a plurality of enriched cfDNA molecules or enriched amplicons thereof to generate sequencing data; and
(c) determining methylation profiles of the cfDNA molecules from the sequencing data and further detecting a presence or absence of one or more genetic variants in cfDNA molecules in the sample to detect the presence or absence of residual disease in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the sample is or is derived from a blood sample of the subject.

### Claim 3 (depends on 2)

The method of claim 2, wherein sequencing adaptors are attached to the cfDNA molecules prior to enriching.

### Claim 4 (depends on 3)

The method of claim 3, wherein the sequencing adaptors comprise molecular barcodes.

### Claim 5 (depends on 1)

The method of claim 1, wherein the enriching comprises a differential tiling of the oligonucleotide probes.

### Claim 6 (depends on 5)

The method of claim 5, wherein the differential tiling has a depth of about 2×, 3×, 4×, 5×, 6×, 8×, 9×, 10×, 15×, 20×, 50× or more.

### Claim 7 (depends on 5)

The method of claim 5, wherein enriched cfDNA molecules or amplicons thereof are amplified prior to sequencing.

### Claim 8 (depends on 1)

The method of claim 1, wherein the plurality of genomic regions comprise one or more sequences selected from the group consisting of exons, introns, promoters, 3′ untranslated regions, 5′ untranslated regions, enhancers and splice sites.

### Claim 9 (depends on 8)

The method of claim 8, wherein a genomic region of the plurality of genomic regions comprises a transcription start site in a promoter region of a tumor suppressor gene.

### Claim 10 (depends on 1)

The method of claim 1, wherein the plurality of genes or genomic regions are part of a sequencing panel that is at least 150 kb in size.

### Claim 11 (depends on 1)

The method of claim 1, wherein the sequencing is massively parallel sequencing that sequences at least 10 million polynucleotide molecules.

### Claim 12 (depends on 1)

The method of claim 1, wherein the sequencing data comprises at least 1 billion, 1.1 billion, 1.2 billion, 1.5 billion, 2 billion, 2.5 billion, 3 billion, 3.5 billion, 4 billion, 4.5 billion, 5 billion, 5.5 billion, 6 billion, 6.5 billion, 7 billion, 8 billion, 9 billion or 10 billion base pairs.

### Claim 13 (depends on 1)

The method of claim 1, wherein a read budget is selected that identifies the total number of base reads to be allocated to the sample, wherein the sample comprises a predetermined amount of DNA.

### Claim 14 (depends on 1)

The method of claim 1, wherein the sequencing is performed at a depth of at least 50,000 reads per base, at least 100,000 reads per base, or at least 120,000 reads per base.

### Claim 15 (depends on 14)

The method of claim 14, wherein the reads per base represent at least 5,000 original cfDNA molecules in the sample.

### Claim 16 (depends on 1)

The method of claim 1, wherein the subject does not have a cancer that is detectable by imaging methods.

### Claim 17 (depends on 15)

The method of claim 15, wherein the imaging method is positron emission tomography scan, magnetic resonance imaging, X-ray, computerized axial tomography scan, ultrasound, or a combination thereof.

### Claim 18 (depends on 1)

The method of claim 1, wherein the cancer is colorectal cancer.

### Claim 19 (depends on 18)

The method of claim 18, wherein the colorectal cancer is detected at a specificity of at least 80% or greater.

### Claim 20 (depends on 19)

The method of claim 19, wherein the plurality of genes or genomic regions is selected for enrichment to detect the colorectal cancer at a positive predictive value (PPV) of at least 60%.

### Claim 21 (depends on 1)

The method of claim 1, wherein sequence reads from the sequencing data are mapped to a reference sequence.

### Claim 22 (depends on 21)

The method of claim 21, wherein the detecting one or more genetic variants in the cfDNA molecules comprises determining a consensus sequence from sequence reads obtained from the sequence data to reduce errors from amplification or sequencing.

### Claim 23 (depends on 22)

The method of claim 22, wherein the consensus sequence is performed on a molecule-by-molecule basis or a base-by-base basis.

### Claim 24 (depends on 22)

The method of claim 22, wherein the consensus sequence is based on assessing probabilities of each of the potential nucleotides based on observed sequence output and the sequencing and amplification error profiles characteristics of an individual sample, a batch of sample, or a reference set of samples.

### Claim 25 (depends on 22)

The method of claim 22, wherein molecular barcodes are used to group the sequencing reads into families derived from original individual cfDNA molecules, wherein the consensus sequence is generated for the family either on a molecule-by-molecule basis or a base-by-base basis.

### Claim 26 (depends on 1)

The method of claim 1, wherein a frequency of nucleotides in the sample is determined by comparing it to a frequency of germline DNA from the subject.

### Claim 27 (depends on 1)

The method of claim 1, wherein the genetic variants are single nucleotide variants (SNVs) and/or insertions or deletions (indels).
